Prasugrel approved by the FDA: Difference between revisions
(New page: July 10 by C. Michael Gibson, M.S., M.D. (click here for Dr. Gibson's disclosures) The Food and Drug Administration announced today that Prasugrel (which will ...) |
No edit summary |
||
| Line 1: | Line 1: | ||
July 10 by C. Michael Gibson, M.S., M.D. (click [[C. Michael Gibson|here]] for Dr. Gibson's disclosures) | July 10 by C. Michael Gibson, M.S., M.D. (click [[C. Michael Gibson|here]] for Dr. Gibson's disclosures) | ||
The Food and Drug Administration announced today that [[Prasugrel]] (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. | The Food and Drug Administration announced today that [[Prasugrel]] (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. A panel convened by the FDA had previously voted 9-0 in a recommendation for approval on February 3rd, 2009. | ||
It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg. | It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg. | ||
The drug is marketed by both Eli Lilly and Daiichi-Sankyo. | The drug is marketed by both Eli Lilly and Daiichi-Sankyo. | ||
Revision as of 20:52, 10 July 2009
July 10 by C. Michael Gibson, M.S., M.D. (click here for Dr. Gibson's disclosures)
The Food and Drug Administration announced today that Prasugrel (which will be sold under the name Effient) is now approved for clinical use. The drug's label indicates that the drug is effective in reducing the risk of stroke and heart attack in patients undergoing percutaneous intervention and will carry a black label warning regarding an increased risk of potentially fatal bleeding. A panel convened by the FDA had previously voted 9-0 in a recommendation for approval on February 3rd, 2009.
It is notable that there are two approved maintenance doses: 10 mg which was studied in the Triton TIMI 38 trial, and a reduced dose of 5 mg.
The drug is marketed by both Eli Lilly and Daiichi-Sankyo.